Background: Plasma-derived factor XIII (FXIII) concentrate is an effective treatment for FXIII deficiency. We describe adverse drug reactions (ADRs) reported during pharmacovigilance monitoring of Fibrogammin®/Corifact® and review published safety data. Methods: Postmarketing safety reports recorded by CSL Behring from June 1993 to September 2013 were analyzed. Clinical studies published during the same period were also reviewed. Results: Commercial data indicated that 1,653,450,333 IU FXIII concentrate were distributed over the review period, equivalent to 1,181,036 doses for a 70 kg patient. 75 cases were reported (one/15,700 standard doses or 22,046,000 IU). Reports of special interest included 12 cases of possible hypersensitivity reactions (one/98,400 doses or 137,787,500 IU), 7 with possible thromboembolic events (one/168,700 doses or 236,207,200 IU), 5 of possible inhibitor development (one/236,200 doses or 330,690,100 IU), and 20 of possible pathogen transmission (one/59,100 doses or 82,672,500 IU). 19 pathogen transmission cases involved viral infection; 4 could not be analyzed due to insufficient data, but for all others a causal relationship to the product was assessed as unlikely. A review of published literature revealed a similar safety profile. Conclusion: Assessment of ADRs demonstrated that FXIII concentrate carries a low risk of ADRs across various clinical situations, suggesting a favorable safety profile.

1.
Hsieh L, Nugent D: Factor XIII deficiency. Haemophilia 2008;14:1190-1200.
2.
Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E: Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011;91:931-972.
3.
Odame JE, Chan AK, Wu JK, Breakey VR: Factor XIII deficiency management: a review of the literature. Blood Coagul Fibrinolysis 2014;25:199-205.
4.
Lusher J, Pipe SW, Alexander S, Nugent D: Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010;16:316-321.
5.
Fadoo Z, Merchant Q, Rehman KA: New developments in the management of congenital factor XIII deficiency. J Blood Med 2013;4:65-73.
6.
Levy JH, Greenberg C: Biology of factor XIII and clinical manifestations of factor XIII deficiency. Transfusion 2013;53:1120-1131.
7.
Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RA, Seifried E, Oldenburg J, Study Group: International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007;97:914-921.
8.
Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, Erwin PJ, Montori VM, Roback JD: The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 2010;50:1370-1383.
9.
O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM, British Committee for Standards in Haematology BTTF: guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
10.
Nugent D: Corifact/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012;130(suppl 2):S12-14.
11.
Dreyfus M, Barrois D, Borg JY, Claeyssens S, Torchet MF, Arnuti B, Pautard B; Groupe dʼEtudes Francophone du FXIII: Successful long-term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost 2011;9:1264-1266.
12.
James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Lee CA, Martinez-Perez O, McLintock C, Peyvandi F, Philipp C, Wilkinson J, Winikoff R: Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 2011;158:124-134.
13.
Lorenz R, Born P, Olbert P, Classen M: Factor XIII substitution in ulcerative colitis. Lancet 1995;345:449-450.
14.
Wozniak G, Noll T, Akinturk H, Thul J, Muller M: Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. Ann N Y Acad Sci 2001;936:617-620.
15.
Korte WC, Szadkowski C, Gahler A, Gabi K, Kownacki E, Eder M, Degiacomi P, Zoller N, Devay J, Lange J, Schnider T: Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009;110:239-245.
16.
Godje O, Haushofer M, Lamm P, Reichart B: The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 1998;46:263-267.
17.
Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H: Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006;54:26-33.
18.
Grothaus-Pinke B, Gunzelmann S, Fauser AA, Kiehl MG: Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience. Transplantation 2001;72:1456-1458.
19.
Demesmay K, Tissot E, Bulabois CE, Bertrand MA, Racadot E, Woronoff-Lemsi MC, Cahn JY, Deconinck E: Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases. Transplantation 2002;74:1190-1192.
20.
Reid PC, Coker A, Coltart R: Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG 2000;107:320-322.
21.
Szanto T, Salmela B, Makipernaa A, Armstrong E, Lassila R: Management of acute myocardial infarction in a patient with factor XIII deficiency using prophylactic factor replacement therapy. Haemophilia 2008;14:163-165.
22.
Boehlen F, Casini A, Chizzolini C, Mansouri B, Kohler HP, Schroeder V, Reber G, de Moerloose P: Acquired factor XIII deficiency: a therapeutic challenge. Thromb Haemost 2013;109:479-487.
23.
Jantsch-Plunger V, Beck G, Maurer W: PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus. Vox Sang 1995;69:352-354.
24.
Matayoshi T, Omi T, Sakai N, Kawana S: Clinical significance of blood coagulation factor XIII activity in adult Henoch-Schonlein purpura. J Nippon Med Sch 2013;80:268-278.
25.
Brackmann HH, Egbring R, Ferster A, Fondu P, Girardel JM, Kreuz W, Masure R, Miloszewski K, Stibbe J, Zimmermann R, et al.: Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995;74:622-625.
26.
Bregenzer N, Caesar I, Andus T, Hamling J, Malchow H, Schreiber S, Scholmerich J: Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group. Z Gastroenterol 1999;37:999-1004.
27.
Nugent DJ: Prophylaxis in rare coagulation disorders - factor XIII deficiency. Thromb Res 2006;118(suppl 1):S23-28.
28.
Ashley C, Chang E, Davis J, Mangione A, Frame V, Nugent DJ: Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia 2015;21:102-108.
29.
Anwar R, Miloszewski KJ: Factor XIII deficiency. Br J Haematol 1999;107:468-484.
30.
Muszbek L, Bagoly Z, Cairo A, Peyvandi F: Novel aspects of factor XIII deficiency. Curr Opin Hematol 2011;18:366-372.
31.
Acharya SS, Coughlin A, Dimichele DM, North American Rare Bleeding Disorder Study Group: Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248-256.
32.
Groener A, Nowak T, Popp B, Schaefer W: A plasma-derived FXIII concentrate with a very high margin of virus safety for the treatment of congenital FXIII deficiency. XXIII Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting, Kyoto, Japan. J Thromb Haemost 2011;9(suppl 2): 222.
33.
Velthove KJ, Over J, Abbink K, Janssen MP: Viral safety of human plasma-derived medicinal products: impact of regulation requirements. Transfus Med Rev 2013;27:179-183.
34.
Narick C, Triulzi DJ, Yazer MH: Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012;52:160-165.
35.
Yang L, Stanworth S, Baglin T: Cryoprecipitate: an outmoded treatment? Transfus Med 2012;22:315-320.
36.
Jacob D, Marron B, Ehrlich J, Rutherford PA: Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf 2013;5:105-112.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.